1. Home
  2. QMCO vs BMEA Comparison

QMCO vs BMEA Comparison

Compare QMCO & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum Corporation

QMCO

Quantum Corporation

N/A

Current Price

$5.21

Market Cap

99.5M

Sector

Technology

ML Signal

N/A

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$1.29

Market Cap

90.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QMCO
BMEA
Founded
1980
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
99.5M
90.5M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
QMCO
BMEA
Price
$5.21
$1.29
Analyst Decision
Buy
Strong Buy
Analyst Count
1
7
Target Price
$13.00
$8.71
AVG Volume (30 Days)
523.2K
971.7K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$372,827,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.65
N/A
52 Week Low
$4.89
$0.87
52 Week High
$24.40
$3.08

Technical Indicators

Market Signals
Indicator
QMCO
BMEA
Relative Strength Index (RSI) 33.06 50.25
Support Level $4.89 $1.24
Resistance Level $8.27 $1.41
Average True Range (ATR) 0.53 0.10
MACD -0.03 0.01
Stochastic Oscillator 16.67 68.92

Price Performance

Historical Comparison
QMCO
BMEA

About QMCO Quantum Corporation

Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: